Literature DB >> 21822592

Renal complications of Castleman's disease: report of two cases and analysis of 75 cases.

Xiang-Gui Yuan1, Wen Hu, Fei-Fei Chen, Bin-Feng Huang, Xiao-Ying Zhao.   

Abstract

Biopsy-proven renal complications of Castleman's disease (CD) are rare and current knowledge is largely based on sporadic case reports. We reported two more cases, both of which were multicentric CD with hyaline-vascular pathological pattern and presented with chronic renal failure. Case 1 was multicentric CD with renal mesangial proliferative glomerulonephritis complications, and case 2 was multicentric CD with membranoproliferative glomerulonephritis-like complications. Although both were eventually administered corticosteroids combined with cytotoxic drugs, both behaved in an aggressive and relapsing manner. We then made an analysis of 75 cases of biopsy-proven renal complications of CD (including our two cases) which were reported in 51 English literatures from January 1954 to March 2011. We found that the clinical and histological findings of renal complications of CD were heterogeneous. Death was observed in 17% patients after a median follow-up time of 22 months (0-204 months) since histological diagnosis of renal complications. The estimated 5-year cumulative survival rate was 75%. Better understanding and therapeutic interventions are required in further investigations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822592     DOI: 10.1007/s10157-011-0499-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  16 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephroitc syndrome.

Authors:  S R Humpherys; K E Holley; L H Smith; D C McIlrath
Journal:  Mayo Clin Proc       Date:  1975-06       Impact factor: 7.616

Review 3.  Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies.

Authors:  G Ruggieri; P Barsotti; G Coppola; C Spinelli; A Balducci; F R Ventola; G d'Adamo; M V Tata; V Marinozzi
Journal:  Am J Nephrol       Date:  1990       Impact factor: 3.754

4.  Kidney involvement in multicentric castleman disease.

Authors:  Sumeet Suneja; Mala Chidambaram; Andrew M Herzenberg; Joanne M Bargman
Journal:  Am J Kidney Dis       Date:  2008-11-06       Impact factor: 8.860

5.  Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease.

Authors:  S Paydas; G Gonlusen; Y Sagliker
Journal:  Nephron       Date:  1995       Impact factor: 2.847

6.  Castleman disease and renal amyloidosis.

Authors:  I Kazes; G Deray; C Jacobs
Journal:  Ann Intern Med       Date:  1995-03-01       Impact factor: 25.391

7.  Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6.

Authors:  J V Castell; M J Gómez-Lechón; M David; R Fabra; R Trullenque; P C Heinrich
Journal:  Hepatology       Date:  1990-11       Impact factor: 17.425

8.  Proliferative glomerulonephritis with monoclonal IgG deposits.

Authors:  Samih H Nasr; Anjali Satoskar; Glen S Markowitz; Anthony M Valeri; Gerald B Appel; Michael B Stokes; Tibor Nadasdy; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

Review 9.  Castleman disease: an update on classification and the spectrum of associated lesions.

Authors:  Danielle M P Cronin; Roger A Warnke
Journal:  Adv Anat Pathol       Date:  2009-07       Impact factor: 3.875

10.  A case of Castleman's disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis.

Authors:  Toshiro Sugimoto; Jun Ito; Naoko Takeda; Ippei Gasyu; Tsutomu Okazaki; Masayoshi Sakaguchi; Norihisa Osawa; Yuki Tanaka; Kazumasa Oka; Takashi Uzu; Atsunori Kashiwagi
Journal:  Am J Med Sci       Date:  2008-06       Impact factor: 2.378

View more
  11 in total

1.  Multicentric Castleman's disease with renal amyloidosis and mesangial proliferative glomerulonephritis: a case report.

Authors:  Zhicheng Tan; Lihua Wang; Chen Wang; Lifang Gao; Yanrong Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Focal segmental glomerulosclerosis associated with cutaneous and systemic plasmacytosis.

Authors:  Shinsuke Isobe; Naro Ohashi; Naoko Katahashi; Sayaka Ishigaki; Naoko Tsuji; Takayuki Tsuji; Akihiko Kato; Yoshihide Fujigaki; Akira Shimizu; Hideo Yasuda
Journal:  CEN Case Rep       Date:  2017-09-22

3.  A Case of Retroperitoneal Castleman's Disease and an Update on the Latest Evidence.

Authors:  Eleftherios Spartalis; Petros Charalampoudis; Apostolos Kandilis; Antonios Athanasiou; Petros Tsaparas; Athanasios Voutsarakis; Ioannis D Kostakis; Dimitrios Dimitroulis; Evanthia Svolou; Penelope Korkolopoulou; Nikolaos Nikiteas; Gregory Kouraklis
Journal:  Case Rep Surg       Date:  2014-11-05

4.  Castleman disease mimicking systemic lupus erythematosus: A case report.

Authors:  Li Wang; Hua Chen; Jing Shi; Hao Tang; Hang Li; Wenjie Zheng; Fengchun Zhang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

Review 5.  Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.

Authors:  Amélie Leurs; Viviane Gnemmi; Arnaud Lionet; Loïc Renaud; Jean-Baptiste Gibier; Marie-Christine Copin; Eric Hachulla; Pierre-Yves Hatron; David Launay; David Fajgenbaum; Louis Terriou
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 8.786

6.  HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.

Authors:  Maria Brito Nunes; Samuel Rotman; Francois-Regis Duss; Matthieu Halfon
Journal:  BMJ Case Rep       Date:  2020-01-06

Review 7.  Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.

Authors:  Ryosuke Saiki; Kan Katayama; Yosuke Hirabayashi; Keiko Oda; Mika Fujimoto; Tomohiro Murata; Ayako Nakajima; Kaoru Dohi
Journal:  BMC Nephrol       Date:  2021-06-09       Impact factor: 2.388

8.  Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor: A case report.

Authors:  Yoshitaka Furuto; Hirotsugu Hashimoto; Hajime Horiuti; Yuko Shibuya
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

9.  Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage.

Authors:  Yuhei Noda; Yosuke Saka; Akihisa Kato; Tetsushi Mimura; Tomohiko Naruse
Journal:  Clin Nephrol Case Stud       Date:  2018-06-22

Review 10.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.